伴有表皮生长因子受体突变的大细胞神经内分泌癌：肺腺癌可能的转化形式 - Suppr

Suppr

超能文献

Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.

作者信息

Yanagisawa Satoru, Morikawa Naoto, Kimura Yuichiro, Nagano Yoko, Murakami Kazuhiro, Tabata Toshiharu

机构信息

Department of Respiratory Medicine, Tohoku Kosei Nenkin Hospital, Sendai, Japan.

出版信息

Respirology. 2012 Nov;17(8):1275-7. doi: 10.1111/j.1440-1843.2012.02258.x.

DOI:10.1111/j.1440-1843.2012.02258.x

PMID:22943430

Abstract

摘要

相似文献

Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.

Respirology. 2012 Nov;17(8):1275-7. doi: 10.1111/j.1440-1843.2012.02258.x.

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.

Ann Oncol. 2012 Dec;23(12):3188-3189. doi: 10.1093/annonc/mds525. Epub 2012 Oct 18.

Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.

Intern Med. 2017;56(15):2013-2017. doi: 10.2169/internalmedicine.56.7452. Epub 2017 Aug 1.

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.

J Clin Oncol. 2011 Dec 1;29(34):e819-22. doi: 10.1200/JCO.2011.36.2251. Epub 2011 Oct 31.

Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.

Integr Cancer Ther. 2011 Jun;10(2):127-37. doi: 10.1177/1534735410387599. Epub 2010 Dec 8.

Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.

Chemotherapy. 2016;61(1):41-50. doi: 10.1159/000440941. Epub 2015 Nov 1.

Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.

Medicine (Baltimore). 2017 May;96(21):e6985. doi: 10.1097/MD.0000000000006985.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.

Ann Oncol. 2010 Nov;21(11):2233-2239. doi: 10.1093/annonc/mdq246. Epub 2010 May 5.

Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.

Korean J Intern Med. 2014 Nov;29(6):830-3. doi: 10.3904/kjim.2014.29.6.830. Epub 2014 Oct 31.

引用本文的文献

Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma.

Front Oncol. 2024 Oct 22;14:1449490. doi: 10.3389/fonc.2024.1449490. eCollection 2024.

Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review.

Transl Lung Cancer Res. 2023 Apr 28;12(4):837-856. doi: 10.21037/tlcr-22-867. Epub 2023 Mar 22.

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.

Int J Mol Sci. 2022 Apr 9;23(8):4164. doi: 10.3390/ijms23084164.

Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases.

World J Clin Cases. 2021 Jun 26;9(18):4617-4626. doi: 10.12998/wjcc.v9.i18.4617.

Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities.

Front Oncol. 2021 Apr 15;11:650293. doi: 10.3389/fonc.2021.650293. eCollection 2021.

[Mechanism of Histologic Transformation of Drive Gene Positive Lung Adenocarcinoma in Targeted Therapy and Treatment Strategy].

Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):701-709. doi: 10.3779/j.issn.1009-3419.2020.102.22. Epub 2020 Aug 6.

Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease.

Onco Targets Ther. 2019 Jul 10;12:5545-5549. doi: 10.2147/OTT.S204689. eCollection 2019.

Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Int J Clin Oncol. 2018 Apr;23(2):235-242. doi: 10.1007/s10147-017-1211-1. Epub 2017 Nov 7.

Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.

Intern Med. 2017;56(15):2013-2017. doi: 10.2169/internalmedicine.56.7452. Epub 2017 Aug 1.

Treatment of lung large cell neuroendocrine carcinoma.

Tumour Biol. 2016 Jun;37(6):7047-57. doi: 10.1007/s13277-016-5003-4. Epub 2016 Mar 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.

作者信息

Yanagisawa Satoru, Morikawa Naoto, Kimura Yuichiro, Nagano Yoko, Murakami Kazuhiro, Tabata Toshiharu

机构信息

Department of Respiratory Medicine, Tohoku Kosei Nenkin Hospital, Sendai, Japan.

出版信息

Respirology. 2012 Nov;17(8):1275-7. doi: 10.1111/j.1440-1843.2012.02258.x.

DOI:10.1111/j.1440-1843.2012.02258.x

PMID:22943430

Abstract

摘要

相似文献

Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.

Respirology. 2012 Nov;17(8):1275-7. doi: 10.1111/j.1440-1843.2012.02258.x.

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.

Ann Oncol. 2012 Dec;23(12):3188-3189. doi: 10.1093/annonc/mds525. Epub 2012 Oct 18.

Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.

Intern Med. 2017;56(15):2013-2017. doi: 10.2169/internalmedicine.56.7452. Epub 2017 Aug 1.

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.

J Clin Oncol. 2011 Dec 1;29(34):e819-22. doi: 10.1200/JCO.2011.36.2251. Epub 2011 Oct 31.

Integr Cancer Ther. 2011 Jun;10(2):127-37. doi: 10.1177/1534735410387599. Epub 2010 Dec 8.

Chemotherapy. 2016;61(1):41-50. doi: 10.1159/000440941. Epub 2015 Nov 1.

Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.

Medicine (Baltimore). 2017 May;96(21):e6985. doi: 10.1097/MD.0000000000006985.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.

Ann Oncol. 2010 Nov;21(11):2233-2239. doi: 10.1093/annonc/mdq246. Epub 2010 May 5.

Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.

Korean J Intern Med. 2014 Nov;29(6):830-3. doi: 10.3904/kjim.2014.29.6.830. Epub 2014 Oct 31.

引用本文的文献

Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma.

Front Oncol. 2024 Oct 22;14:1449490. doi: 10.3389/fonc.2024.1449490. eCollection 2024.

Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review.

Transl Lung Cancer Res. 2023 Apr 28;12(4):837-856. doi: 10.21037/tlcr-22-867. Epub 2023 Mar 22.

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.

Int J Mol Sci. 2022 Apr 9;23(8):4164. doi: 10.3390/ijms23084164.

Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases.

World J Clin Cases. 2021 Jun 26;9(18):4617-4626. doi: 10.12998/wjcc.v9.i18.4617.

Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities.

Front Oncol. 2021 Apr 15;11:650293. doi: 10.3389/fonc.2021.650293. eCollection 2021.

[Mechanism of Histologic Transformation of Drive Gene Positive Lung Adenocarcinoma in Targeted Therapy and Treatment Strategy].

Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):701-709. doi: 10.3779/j.issn.1009-3419.2020.102.22. Epub 2020 Aug 6.

Onco Targets Ther. 2019 Jul 10;12:5545-5549. doi: 10.2147/OTT.S204689. eCollection 2019.

Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Int J Clin Oncol. 2018 Apr;23(2):235-242. doi: 10.1007/s10147-017-1211-1. Epub 2017 Nov 7.

Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.

Intern Med. 2017;56(15):2013-2017. doi: 10.2169/internalmedicine.56.7452. Epub 2017 Aug 1.

Treatment of lung large cell neuroendocrine carcinoma.

Tumour Biol. 2016 Jun;37(6):7047-57. doi: 10.1007/s13277-016-5003-4. Epub 2016 Mar 4.